Arena Pharmaceuticals, Inc. (ARNA), developer of the weight management drug Belviq, Tuesday said its pulmonary arterial hypertension drug, APD811, was granted orphan drug status by the US Food and Drug Administration.
"We are pleased with the OOPD's designation of orphan drug status for the active moiety of APD811, and we look forward to advancing this drug candidate into a Phase 2 clinical trial program later this year," said Craig Audet, Senior VP of Arena.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.